"We are on the verge of a revolution in medicine: understanding, treating, and ultimately preventing the causes of degenerative aging. But medical revolutions only happen if we all stand up in support of funding and research. We did it for cancer. We're doing it for Alzheimer's. We can do it for aging - and create an era of longer, healthier lives!"

Email Contact
reason -at- fightaging -dot- org

  
Search

The Causes of Aging
Accumulating AGEs
Buildup of Amyloid Between Cells
The Failing Immune System
Declining Lysosomal Function
Mitochondrial DNA Damage
Senescent Cells
Other Causes of Aging

Required Reading
Calorie Restriction
The Community, Visualized
Cryonics
Engineered Negligible Senescence
Envisaging a World Without the FDA
Healthy Life Extension Explained
Introductory Articles
Longevity Meme Newsletter
The Odds of Human Longevity Mutations
The Need For Activism and Advocacy
Stem Cells, Regenerative Medicine
Twelve Ways to Extend Mouse Life Span
The Vital Debate in Aging Research
What is Anti-Aging?

Initiatives
Biogerontology Research Foundation
Campaign Against Aging
Campaign for Aging Research
LifeStar Institute
Immortality Institute
Maximum Life Foundation
Methuselah Foundation
Mprize for Longevity Research
Science Against Aging (Translate)
SENS Foundation

Benefiting From Medical Research
How to Read Scientific Research
Researching Therapies and Clinical Trials

Objections Answered
Boredom
Inequality and Economics
Overpopulation
Stagnation
Being Older for Longer?
What About Retirement?

Recent Entries

  • The Conservative View of Progress in Applied Cancer Research
  • More on Stem Cell Technology and the Rise of Medical Tourism
  • Resting Metabolic Rate and Aging, Another of Metabolism's Complexities
  • Capabilities in Stem Cell Science Are Advancing Rapidly
  • Incentives and Cryonics
  • Videos From the Foresight 2010 Conference
  • A Steady Flow of New Donors at the Methuselah Foundation
  • Manipulating Fat in the Context of Slowing Aging
  • On Medical Tourism For Stem Cell Therapies
  • Cells, Hearts, and Brains
  • Rapamycin Research Rolls Onward
  • Reversing Blindness in Retinitis Pigmentosa With Stem Cells
  • The Body Does Work to Break Down Damaging Aggregates
  • A Few Cancer Stem Cell Articles
  • The Latest on Mitochondrial Uncoupling
  • Longevity Research at the Science Network
  • Journalists Are In the Business of Gathering Eyeballs, Not Truth
  • @ging, a New Aging Science Blog
  • Redefining Bionics Again
  • Encouraging Transparency in Life Science Fundraising

    Blogs of Interest
    @ging
    Accelerating Future
    Ageing Research
    Alcor News
    Al Fin Longevity
    April's CR Diary
    Andart
    Biology of Aging
    Biosingularity
    CRON Diary
    Cryonics Society
    Depressed Metabolism
    Distributed Republic
    Ethical Technology Blog
    Existence is Wonderful
    Foresight Institute
    Future Current
    FuturePundit
    grailsearch.org
    green light go
    HumanPlus
    In Search of Enlightenment
    Marginal Revolution
    Maximum Life Foundation Blog
    Metamagician and the Hellfire Club
    Metamodern
    Methuselah Foundation Blog
    Mises Economics Blog
    Ouroboros
    Overcoming Bias
    Pimm - Partial immortalization
    Responsible Nanotechnology
    ScienceBlogs
    Sentient Developments
    Singularity Hub
    Singularity Institute Blog
    Sonia Arrison
    The Speculist
    The Technological Citizen

    Archives (Monthly)

    March 2010
    February 2010
    January 2010
    December 2009
    November 2009
    October 2009
    September 2009
    August 2009
    July 2009
    June 2009
    May 2009
    April 2009
    March 2009
    February 2009
    January 2009
    December 2008
    November 2008
    October 2008
    September 2008
    August 2008
    July 2008
    June 2008
    May 2008
    April 2008
    March 2008
    February 2008
    January 2008
    December 2007
    November 2007
    October 2007
    September 2007
    August 2007
    July 2007
    June 2007
    May 2007
    April 2007
    March 2007
    February 2007
    January 2007
    December 2006
    November 2006
    October 2006
    September 2006
    August 2006
    July 2006
    June 2006
    May 2006
    April 2006
    March 2006
    February 2006
    January 2006
    December 2005
    November 2005
    October 2005
    September 2005
    August 2005
    July 2005
    June 2005
    May 2005
    April 2005
    March 2005
    February 2005
    January 2005
    December 2004
    November 2004
    October 2004
    September 2004
    August 2004
    July 2004
    June 2004
    May 2004
    April 2004
    March 2004
    February 2004
    January 2004

    Creative Commons

    Creative Commons License

    Fight Aging! is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite Fight Aging! content in any way you see fit, the only requirements being that you (a) link to the original, (b) attribute the author, and (c) attribute Fight Aging!.

  • Saturday, May 13, 2006

    Another Side of Learning About Money: Hows and Whys of Research Funding

    I talked a little about money and personal finance in the context of healthy life extension yesterday. Economics is both the root and representation of society and human interaction; modest understanding of the flows and practicalities will bring you great advantage in your endeavors.

    I imagine that many of the folk reading Fight Aging! are very interested in the rate and details of progress in medical research, and specifically in work that may lead to healthy life extension technologies. If you're interested in medical progress and don't understand the workings of investment and commercialization, then you are left largely blind. You will not understand why some work succeeds while other work does not; you will fail to grasp the full significance of many news stories; you will not have a realistic view of the near future of medicine; you will not understand how and why some actions, events and situations damage progress and hinder the advance of new medical technology from laboratory to clinic.

    Medical research funding in the US is approximately 30-40% public, 50-60% private for-profit and 10% philanthropic; most to the hard work of bringing science from laboratory to market is accomplished with private funding. So best to learn a little about how that process and culture works, no? A good place to start, with respect to recent private investment in healthy life extension and related research, might be the book "The Quest for Human Longevity."

    Most other popular books on human longevity are focused almost exclusively on scientific ideas and breakthroughs in life-extension research, and they typically avoid any money talks as inappropriate subject. ... This somewhat idealistic perspective is challenged in a new book, which describes in a great detail how important money is in modern entrepreneurial world of life-extension and anti-aging research business. The book provides an alternative, more realistic perspective that financial incentives are driving scientific innovations in anti-aging studies by stimulating researchers to take risks and to work really hard.

    While thinking along these lines, I bumped into a short article on venture investment in biotechnology today that gives some insight into the way in which investors think.

    While the public markets for biotechnology companies have historically been an opportunity for very significant returns, the recent past markets have not been as attractive. With significant downward pressure on public valuations for many biotechnology companies, venture capital investors have had to evolve some of their thinking.

    ...

    With the markets valuing many new public companies in the range around $150 million (as opposed to $300 million), investors can no longer invest in companies that require $80-100 million to mature to the point where they can go public. This has forced companies and investors to be much more capital efficient and to pursue creative paths to product development and ultimately commercialization. This might manifest in the pursuit of more developed assets or the adoption of clinical development plans that can be abbreviated.

    Investment environments are something like the weather - too many variables to predict well at the smaller scale, but big storms rarely come out of the blue. Investors react to this weather, which can make all the difference in funding of early stage companies, more speculative research, or research that will take longer to mature.

    This is just a small slice of life from a broad, changing culture, however. I'm not familiar with the breadth of venture investment and private research funding, and neither do you need to be - the general basics, incentives and practicalities of venture investment, growth of companies and commercialization of products are all you need to gain a much better understanding of the world around you. This, like an understanding of money in the context of personal finance, is really nowhere near as hard as you might think. Much of it is intuitive, and the more you look at it, the easier it becomes to figure out the rest.

    Technorati.com: ,

    Posted by Reason

     
    Share |

    Post a comment; thoughtful, considered opinions are valued. Please note that comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.










    Remember personal info?